India Pharma & Healthcare Stocks
Track 15 pharmaceutical and healthcare companies with historical returns, performance rankings, and investment analysis.
What's Driving Pharma Stock Returns?
Updated: Nov 2026India is the "pharmacy of the world"—the largest exporter of generic drugs, supplying 40% of US generic demand and 25% of global medicines. The sector benefits from both export growth and rising domestic healthcare spending.
Current performance: Pharma companies average +26.2% (1Y), while Hospital chains return -8.9%.
Key themes: US FDA approvals (generic launches drive revenue spikes), API manufacturing (China+1 beneficiary), specialty drugs shift, and domestic demand from rising health insurance coverage.
Of the 15 healthcare stocks tracked, 11 delivered positive returns over the past year. The top performer, LAURUSLABS, returned +160.1%, while FORTIS was the weakest at -25.9%. The median return was +6.0%.
Top 5 by 1-Year Return
Pharma Stocks Monthly Returns (Dec'25 – Nov'26)
Compare month-by-month performance. Green = gain, red = loss. Click any ticker for detailed analysis.
| Stock | Dec'25 | Jan'26 | Feb'26 | Mar'26 | Apr'26 | May'26 | Jun'26 | Jul'26 | Aug'26 | Sep'26 | Oct'26 | Nov'26 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LAURUSLABS | +7% | -13% | +11% | -8% | +11% | +24% | +11% | +20% | +5% | +3% | +21% | — | +133.4% |
| DIVISLAB | -1% | -5% | +6% | -7% | +9% | +3% | -1% | +23% | +18% | -2% | +5% | — | +51.6% |
| AUROPHARMA | -4% | +2% | +1% | +7% | +7% | +3% | +11% | +0% | +9% | -3% | +1% | — | +37.1% |
| ZYDUSLIFE | -3% | -3% | +4% | -5% | +2% | +21% | +3% | +1% | +3% | +0% | +7% | — | +32.3% |
| TORNTPHARM | +3% | +3% | +10% | -3% | -1% | +6% | +5% | +11% | -1% | -5% | -4% | — | +25.1% |
| GLENMARK | +5% | -1% | +6% | -0% | +13% | -5% | -3% | +1% | +11% | -6% | -2% | — | +18.2% |
| APOLLOHOSP | -4% | -1% | +13% | -5% | +3% | +7% | +6% | +3% | -1% | -8% | +3% | — | +15.5% |
| MANKIND | -2% | -3% | +6% | -11% | +12% | +6% | +7% | -3% | -2% | +4% | -0% | — | +10.7% |
| DRREDDY | +1% | -4% | +6% | -2% | +5% | -1% | +4% | -15% | +1% | +7% | +10% | — | +8.1% |
| SUNPHARMA | -6% | -7% | +10% | +1% | +3% | -1% | +4% | +7% | -0% | -8% | -2% | — | -2.0% |
| LUPIN | +1% | +2% | +7% | +1% | -0% | -2% | +7% | +1% | -9% | -7% | -1% | — | -2.7% |
| CIPLA | -1% | -12% | +2% | -9% | +7% | +7% | +6% | +1% | -4% | -4% | +2% | — | -9.1% |
| ALKEM | -3% | +3% | +0% | -6% | +2% | +2% | +1% | +3% | -7% | -3% | -1% | — | -9.2% |
| BIOCON | -1% | -7% | +6% | -7% | -0% | +19% | -2% | +2% | -3% | -10% | -5% | — | -11.6% |
| FORTIS | -4% | -4% | +11% | -16% | +16% | +1% | +3% | -1% | -4% | -15% | -0% | — | -16.3% |
Industry Breakdown
All Healthcare Stocks
Sorted by market capitalization. The three largest — SUNPHARMA, DIVISLAB, TORNTPHARM — represent 43% of the sector.
| Stock | Market Cap | 1Y Return | 5Y Return | 10Y Return |
|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries | ₹4.3L Cr | +5.6% | +144.8% | +145.9% |
| DIVISLAB Divi's Laboratories Limited | ₹2.6L Cr | +49.0% | +104.4% | +723.8% |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹1.8L Cr | +30.0% | +217.2% | +562.7% |
| LAURUSLABS Laurus Labs Limited | ₹1.3L Cr | +160.1% | +307.3% | N/A |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1.2L Cr | +24.1% | +130.5% | +267.1% |
| APOLLOHOSP Apollo Hospitals Enterprise | ₹1.2L Cr | +8.1% | +87.6% | +522.9% |
| DRREDDY Dr. Reddy's Laboratories | ₹1.1L Cr | +6.0% | +45.8% | +139.0% |
| CIPLA Cipla Limited | ₹1.1L Cr | -12.2% | +49.3% | +168.9% |
| MANKIND Mankind Pharma Limited | ₹1.0L Cr | +2.5% | N/A | N/A |
| AUROPHARMA Aurobindo Pharma Limited | ₹97K Cr | +53.0% | +139.5% | +136.3% |
| LUPIN Lupin Limited | ₹92K Cr | +4.9% | +121.0% | +34.4% |
| GLENMARK Glenmark Pharmaceuticals Limited | ₹65K Cr | +26.5% | +363.0% | +173.4% |
| ALKEM Alkem Laboratories Limited | ₹61K Cr | -6.7% | +34.5% | +266.4% |
| FORTIS Fortis Healthcare Limited | ₹58K Cr | -25.9% | +190.4% | +299.3% |
| BIOCON Biocon Limited | ₹58K Cr | -2.0% | -0.7% | +151.0% |
About India Pharma Stocks
India's pharmaceutical industry is the world's third-largest by volume and a leading exporter of generic drugs. Indian companies manufacture over 60,000 different drug formulations and export to 200+ countries.
Key Investment Themes
- US generics market: India supplies 40% of US generic drug demand. FDA approvals drive revenue spikes.
- API manufacturing: India is the "China+1" beneficiary for Active Pharmaceutical Ingredients sourcing.
- Specialty & complex generics: Higher margins in biosimilars, injectables, and complex molecules.
- Domestic demand: Rising health insurance coverage (Ayushman Bharat) driving volume growth.
- R&D investment: Top players investing in novel drug development beyond generics.
Risks to Watch
- FDA inspections: Warning letters can halt US exports and tank stock prices.
- Pricing pressure: US drug price reforms and consolidation of PBMs squeeze margins.
- Currency volatility: USD/INR impacts export realizations.